Phases of the accumulation of RCVR during primary infection. by Brandon F. Keele (7450001)

The effectiveness of additional rounds of annual 3D-MDA starting in 2023 for three different levels of treatment coverage. by Callum Shaw (15628313)

The effectiveness of the household-based strategy, with different number of teams, treatment radii, and household test aims (HTA). by Callum Shaw (15628313)

Results of ABC fitting—transformed parameters. by Callum Shaw (15628313)

Depletion of xlPTP4A3 inhibits both migration of NCC and uveal melanoma cells. by Selma Maacha (501715)

“…B) Timelapse videomicroscopy of stage 17-derived NCC treated with a pharmacological inhibitor of PTP4A3, a rhodanine derivative (PRL-3 inhibitor I), shows that inhibition of PTP4A3 increases the average of pausing NC cells and strongly decreases the migration velocity of the treated cells (relative to that of vehicle treated cells). …”

Fig 1 - by Khalid Abdul Basit (15332672)

Brief report: Circulating markers of fibrosis are associated with immune reconstitution status in HIV-infected men by F. A. Tobolowsky (4807467)

No viral measurement predicts off-ART rebound or not in d3 or d4 ART RMs. by Brandon F. Keele (7450001)

Rebound kinetics and time to detection following ART discontinuation. by Brandon F. Keele (7450001)

Pre- and early post-ART viral dynamics. by Brandon F. Keele (7450001)

SIV CA-DNA, SIV CA-RNA, and IPDA levels prior to ART interruption using CA-DNA and RNA values and IPDA. by Brandon F. Keele (7450001)

Barcode assessment post rebound. by Brandon F. Keele (7450001)

Reactivation rates. by Brandon F. Keele (7450001)

Fig 1 - by Qiumeng Zhang (4184326)

Oocyst intensity and prevalence. by Lauren M. Childs (593877)

S1 Fig - by Qiumeng Zhang (4184326)

Fig 2 - by Khalid Abdul Basit (15332672)

Summary of all simulated surveillance strategies. by Callum Shaw (15628313)

Model of the observed species density. by Stijn Bruneel (8113409)

Sampling design of the study. by Stijn Bruneel (8113409)